The Chemours Company (CC) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of The Chemours Company (NYSE:CC) from a hold rating to a buy rating in a report published on Thursday morning. They currently have $57.00 price objective on the specialty chemicals company’s stock.
According to Zacks, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. “
CC has been the subject of a number of other research reports. BidaskClub cut shares of The Chemours from a buy rating to a hold rating in a research note on Friday, August 11th. UBS AG upped their price target on shares of The Chemours from $50.00 to $59.00 and gave the company a neutral rating in a report on Friday, November 3rd. Barclays PLC upped their price target on shares of The Chemours from $55.00 to $58.00 and gave the company an overweight rating in a report on Monday, November 6th. Citigroup Inc. upped their price target on shares of The Chemours from $45.00 to $59.00 and gave the company a buy rating in a report on Friday, August 4th. Finally, Jefferies Group LLC upped their price target on shares of The Chemours to $60.00 and gave the company a buy rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The Chemours has an average rating of Buy and a consensus target price of $53.89.
The Chemours (CC) traded down $1.04 during mid-day trading on Thursday, reaching $50.07. 1,859,900 shares of the company’s stock were exchanged, compared to its average volume of 2,477,777. The company has a current ratio of 2.19, a quick ratio of 1.63 and a debt-to-equity ratio of 5.07. The Chemours has a fifty-two week low of $20.22 and a fifty-two week high of $58.08. The stock has a market cap of $9,271.11, a PE ratio of 17.76, a PEG ratio of 0.89 and a beta of 3.59.
The Chemours (NYSE:CC) last released its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.11. The Chemours had a net margin of 13.07% and a return on equity of 121.47%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the previous year, the company earned $0.61 EPS. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. sell-side analysts forecast that The Chemours will post 3.65 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Monday, November 20th will be issued a $0.03 dividend. The ex-dividend date is Friday, November 17th. This represents a $0.12 annualized dividend and a yield of 0.24%. The Chemours’s dividend payout ratio (DPR) is presently 8.28%.
In other The Chemours news, insider E Bryan Snell sold 13,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $49.35, for a total value of $641,550.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David C. Shelton sold 13,337 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $48.48, for a total transaction of $646,577.76. The disclosure for this sale can be found here. Insiders sold a total of 76,520 shares of company stock valued at $4,008,293 over the last 90 days. Company insiders own 1.14% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC grew its position in shares of The Chemours by 6.1% in the 2nd quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock worth $600,289,000 after buying an additional 905,038 shares during the period. Renaissance Technologies LLC grew its position in shares of The Chemours by 10.3% in the 2nd quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock worth $126,736,000 after buying an additional 310,800 shares during the period. Bank of New York Mellon Corp grew its position in shares of The Chemours by 7.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,371,909 shares of the specialty chemicals company’s stock worth $120,042,000 after buying an additional 173,523 shares during the period. JPMorgan Chase & Co. grew its position in shares of The Chemours by 11.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,201,287 shares of the specialty chemicals company’s stock worth $110,969,000 after buying an additional 234,705 shares during the period. Finally, TIAA CREF Investment Management LLC grew its position in shares of The Chemours by 126.5% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock worth $67,843,000 after buying an additional 999,380 shares during the period. Institutional investors and hedge funds own 73.23% of the company’s stock.
About The Chemours
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Chemours Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours Company and related companies with MarketBeat.com's FREE daily email newsletter.